As of 4:01pm ET
| +0.71 / +0.82%|
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. It operates through two segments: Human Pharmaceutical Products and Animal Health. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular and other. The Animal health segment operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. The Animal health products include Rumensin, Tylan, Posilac, Paylean and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.
|David A. Ricks||Chairman, President & Chief Executive Officer|
|Thomas F. Bumol||Senior VP-Biotechnology & Autoimmunity Research|
|Michael R. Meadows||VP & Chief Technology Officer|
|Aarti Shah||Chief Information Officer & SVP-IT|
|Timothy J. Garnett||Chief Medical Officer & VP-Global Medical|